Compare TYRA & SHAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | SHAK |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | 13873 |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2021 | 2014 |
| Metric | TYRA | SHAK |
|---|---|---|
| Price | $33.74 | $62.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 26 |
| Target Price | $47.50 | ★ $117.29 |
| AVG Volume (30 Days) | 749.1K | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 354.17 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,445,306,000.00 |
| Revenue This Year | N/A | $16.58 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.38 |
| 52 Week Low | $8.75 | $59.49 |
| 52 Week High | $40.65 | $142.23 |
| Indicator | TYRA | SHAK |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 28.55 |
| Support Level | $33.29 | N/A |
| Resistance Level | $33.99 | $94.90 |
| Average True Range (ATR) | 1.98 | 3.57 |
| MACD | -0.02 | -2.27 |
| Stochastic Oscillator | 30.44 | 8.00 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.